ArticleTherapeutic advances in respiratory disease2016

Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy.

Carl Selya-Hammer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.